Questions? 10 seconds to sign up
Join the platform
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
March 10, 2026
Approximately 5 minutes
Evaluation Guidelines for siRNA-Loaded Nanomedicines in Japan
1. Background and policy intent
Nucleic acid-based compounds like siRNAs are double-stranded RNA molecules that enable gene silencing but face delivery challenges due to high molecular weight and hydrophilicity. Nanotechnology-based carriers (e.g., liposomes) improve stability and targeting. Issued in March 2016, the guideline promotes appropriate development by addressing quality and nonclinical/early clinical evaluations, applicable to similar nucleic acids. Source: https://www.pmda.go.jp/files/000272264.pdf
2. Target products and eligibility types
Target products encapsulate siRNAs in nanotechnology carriers to enhance pharmacokinetics and intracellular delivery. Eligibility focuses on products overcoming siRNA limitations via carriers, including passive/active targeting types. Principles may apply to other nucleic acids. Source: https://www.pmda.go.jp/files/000272264.pdf
3. Consultation pathway before approval
Case-by-case consultations with PMDA are recommended. The guideline outlines pre-approval considerations for quality attributes, control strategies, and study designs, referencing ICH and EMA/MHLW reflections. Source: https://www.pmda.go.jp/files/000272264.pdf
4. Approval application and review expectations
Applications require detailed quality characterization (particle size, loading efficiency) and safety optimizations. Review focuses on pharmacokinetic behavior, delivery to targets, and toxicity risks, with validated methods and risk-based assessments. Source: https://www.pmda.go.jp/files/000272264.pdf
5. Procedure after approval (post-marketing obligations)
No specific post-marketing section; general principles imply monitoring for long-term safety, especially carrier accumulation and immunotoxicity. Source: https://www.pmda.go.jp/files/000272264.pdf
6. Practical considerations and positioning versus other pathways
Practically, optimize carriers for biodegradability and targeting; evaluate in vitro/in vivo correlations. Positioning integrates with ICH for consistency, differing from standard drugs by nanotechnology-specific evaluations. Source: https://www.pmda.go.jp/files/000272264.pdf
7. Effective date
Issued as PSEHB/ELD Notification No. 0328-17 on March 28, 2016. Source: https://www.pmda.go.jp/files/000272264.pdf
ElendiLabs Regulatory Affairs Team
100+ products successfully registered across global markets. Get unbeatable quotations and expert answers — fast.
Ask Anything
We'll follow up with you personally.
Related Articles
Approximately 5 minutes
Guideline for Liposome Drug Product Development in Japan
Japan’s guideline provides considerations for developing liposome drug products, focusing on chemistry, manufacturing, controls, nonclinical studies, and first-in-human trials to ensure rational development and efficient regulatory review, aligning with ICH standards.
Approximately 5 minutes
Reflection Paper on Block Copolymer Micelle Medicinal Products in Japan
Japan’s reflection paper provides considerations for developing block copolymer micelle drug products, focusing on quality, nonclinical studies, and first-in-human trials to promote appropriate evaluation and prompt patient access, applicable to similar nanotechnology-based products.
Approximately 5 minutes
Reflection Paper on Drug-Agnostic Companion Diagnostics in Japan
Japan’s reflection paper outlines eligibility evaluations, development considerations, and package insert precautions for drug-agnostic companion diagnostics, enabling interchangeable use among approved CDx products to identify patients for multiple therapeutics.
Approximately 5 minutes
Handling of Drug-Agnostic Companion Diagnostics in Japan
Japan’s notification outlines procedures for designating drug-agnostic companion diagnostics (CDx) where multiple approved CDx can be used interchangeably to identify patients for various therapeutics, promoting personalized medicine and patient access.